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Abstract
An integrated understanding of therapeutic plasma exchange (TPE) effects on immunoglobulins, 
autoantibodies, and natural or acquired (vaccine) protective antibodies in patients with 
autoimmune myasthenia gravis (MG) is lacking. Prior studies measured TPE effects in healthy 
volunteers or heterogeneous autoimmune diseases populations. We prospectively profiled plasma 
IgA, IgM, IgG, IgG subclasses (IgG1-4), acetylcholine receptor autoantibodies (AChR+), and 
protective antibodies in patients with AChR+ MG receiving TPE for an exacerbation. TPE was 
performed according to institutional practice and patients were profiled for up to 12 weeks. Ten 
patients were enrolled (median age=72.9 years; baseline MG-Composite=21; median TPE 
treatments=6 during their first course) and all improved. The maximum decrease in all 
immunoglobulins, including AChR autoantibodies, was achieved on the final day of the first TPE 
course (approximately 60–70% reduction). Three weeks post-TPE mean AChR autoantibody, total 
IgG, IgG1 and IgG2 titers were below the reference range and had not recovered to within 20% of 
baseline, whereas other measured immunoglobulins approached baseline values. We did not 
generally observe an “overshoot” of immunoglobulins above pre-TPE levels or accelerated 
recovery of pathologic AChR autoantibodies. Protective antibody profiles showed similar patterns 
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as other IgGs and were detectable at levels associated with protection from infection. A slow 
return to baseline for IgGs (except IgG3) was observed, and we did not observe any obvious effect 
of concomitant medications on this recovery. Collectively, these findings enhance our 
understanding of the immunological effects of TPE and further supports the concept of rapid 
immunoglobulin depletion for the treatment of patients with MG.
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INTRODUCTION
Myasthenia gravis (MG) is a chronic, potentially fatal autoimmune disease characterized by 
circulating autoantibodies directed against epitopes of the post-synaptic muscle membrane, 
including nicotinic acetylcholine receptor (AChR). This autoimmune attack causes weakness 
of voluntary muscles and results in fluctuating weakness that may affect ocular, pharyngeal, 
respiratory, and limb muscles (1). MG is considered a model of IgG mediated autoimmunity 
and previous studies have provided invaluable information on the mechanisms of 
autoimmune disease.
Treatment paradigms for MG include therapies such as intravenous immunoglobulin (IVIg) 
and therapeutic plasma exchange (TPE) (2, 3). Due to its’ ability to rapidly improve patient 
weakness, TPE is commonly used in MG to treat disease exacerbations, prepare patients for 
surgery, and prior to initiating treatment with corticosteroids. The TPE procedure consists of 
filtering venous blood and removing plasma constituents including normal and pathogenic 
immunoglobulins. Afterwards, the removed plasma is usually replaced with fresh frozen 
plasma or albumin (4). While it is known that total autoantibody levels in MG patients drop 
during TPE, the long term effect of TPE on these parameters or the effect on 
immunoglobulin (Ig) subtypes and protective autoantibodies have been understudied in 
patients with MG. Most prior studies have focused on total Ig or autoantibody levels during 
and immediately after TPE (5). Additionally, no studies have simultaneously evaluated Ig 
and autoantibody levels in MG patients. Another long-standing controversy is whether TPE 
therapy elicits an overshoot of Igs or accelerated recovery of pathologic autoantibodies (5, 
6).
The goal of this study was to create a more integrated understanding of TPE effects on Ig, 
autoantibody levels, and protective antibodies. We prospectively profiled the effects of TPE, 
provided as standard of care to AChR autoantibody positive MG patients (AChR MG), on 
IgA, IgM, IgG, IgG subclasses, autoantibodies, and selected protective antibodies.
METHODS
Study design
The study was approved by the Institutional Review Board at the respective clinical sites. 
This study enrolled 10 MG patients who received TPE as standard of care at Duke 
University Medical Center or The University of North Carolina at Chapel Hill Hospital. All 
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patients were initially treated with TPE due to exacerbations of their disease. Approximately 
one plasma volume was exchanged during each TPE procedure and colloid replacement was 
5% albumin in >90% of procedures. It was expected that most patients would initially 
receive 5–6 TPE procedures per standard practice at each institution (7). Patients could 
receive additional TPE procedures if deemed necessary by their treating physician. Any 
concomitant immunosuppressive medications were kept as constant as possible. Clinical 
outcomes and immunoglobulins were measured at baseline (Visit 1), prior to the third (V2) 
and last TPE procedures (V3) and 1, 2, 3, 6, and 12 weeks (V4–8) post-TPE. Data will be 
presented out to 3 weeks post TPE because at 6 and 12 weeks, differences in the treatment of 
patients related to changes in immunosuppressive medications and additional courses of 
TPE introduced variability that made data interpretation difficult. From the screening visit to 
week 3 post-TPE, there were no treatment changes that would confound the analysis. 
Clinical outcomes measured in this study include the validated MG-Composite and MG-
Manual Muscle Testing (MMT). In these two tests, a change in either score of ≥3 points is 
considered clinically significant and defined “improvement” (8, 9). Since prior clinical trials 
of TPE used the change from baseline to 2 weeks post-TPE in clinical scores as primary 
outcomes, this time point was also used to determine response to TPE (10).
Eligibility criteria
The primary inclusion criteria included age at least 18 years, diagnosis of MG based on 
clinical features and detectable serum autoantibodies to AChR, and a clinical indication for 
the use of TPE. Exclusion criteria included a weight <50Kg, a contraindication to treatment 
with TPE (e.g. clinically significant bleeding disorder), muscle specific tyrosine kinase or 
low-density lipoprotein receptor-related protein 4 antibody positive MG, prior history of or 
current thymoma at the time of screening, thymectomy in the past 6 months, and a 
coexisting autoimmune disease that may preclude accurate study assessments.
Immunoglobulin assays
Quantitative immunoglobulins (IgG, IgA, IgM; Duke Clinical Laboratory) and IgG 
subclasses (IgG1, IgG2, IgG3, IgG4; Mayo Medical Laboratories) were performed by rate 
nephelometry and radial immunodiffusion. AChR binding antibody levels (Mayo Medical 
Laboratories) were determined using a quantitative radioimmunoassay. An ELISA assay 
(Kansas City Analytical Services) was used to measure the following vaccination induced 
and natural protective antibodies in serum: anti-tetanus toxoid IgG, anti-diphtheria toxoid 
IgG, anti-varicella zoster virus IgG and anti-Epstein Barr virus viral capsid antigen IgG. 
These antibodies were selected since they are part of the recommended vaccination schedule 
or due to common exposure in the general population.
Data analysis
Demographic data were summarized descriptively as median and range for continuous 
variables and as counts and percentages for categorical parameters. Total Igs, IgG 
subclasses, AChR autoantibody, and protective/vaccination antibody levels were 
summarized as means and standard deviation and plotted graphically by visit. The 
percentage change from baseline was also calculated for each immunoglobulin measured. A 
particular interest of the analysis was to determine the point when immunoglobulin, IgG 
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subtypes, and AChR autoantibody levels variables return to pre-TPE levels and whether 
there is an “overshoot” of immunoglobulin or AChR levels higher than pre-TPE 
measurements. Return of Igs to within 20% of the pre-TPE level was considered “recovery.” 
All analyses were performed using SAS® version 9.1 or later (SAS Institute, Cary, NC, 
USA).
RESULTS
Demographics
Ten AChR MG patients were enrolled. Two patients underwent thymectomy prior to the 
study, none had a history of thymoma and most were on immunosuppressive therapy with 
corticosteroids and/or azathioprine or mycophenolate mofetil (Table 1). None had ever 
received rituximab treatment. Most patients had a moderate severity of weakness at the time 
of enrollment (11). Nine patients completed the study. One patient was withdrawn after Visit 
6 following a stroke that was unrelated to the study procedures.
TPE procedures and clinical outcomes
Patients underwent a median of 6 (range 5–27) TPE procedures during the trial. Sixty-nine 
percent of TPE procedures were performed in the outpatient setting. All patients improved 
following TPE, and the median change from baseline to 2 weeks post-TPE was −10 points 
(−3 to −22) for the MG-composite and −10 points (0 to −44) for the MG-MMT.
Three patients required additional TPE due to refractory disease. Two of these received 
chronic TPE due to an incomplete response to ongoing oral immunosuppressive therapies. 
The third patient had new onset disease and was found to have a thymoma (WHO Type B1) 
after enrollment. This patient received additional TPE procedures prior to an uncomplicated 
thoracoscopic thymectomy. The thymoma patient’s clinical response to TPE was less 
marked and more transient than other patients. She had a 3 point improvement on MG-
composite and 6 point improvement on the MG-MMT 2 weeks after TPE.
IgA, IgM, and total IgG immunoglobulins
All patients showed a reduction following TPE reaching its lowest point on the final day of 
TPE in all patients (Figure 1A). The mean maximum reduction was 69.1%, 79.1%, and 
73.4% for IgA, IgM, and total IgG, respectively (Figure 1B). Recovery of total IgG levels 
following TPE were slower than IgA or IgM. For example, IgA and IgM levels returned to 
within approximately 20% of mean baseline values 3 weeks after completing a course of 
TPE whereas mean total IgG remained 38.5% reduced (Figure 1).
IgG subclasses
TPE rapidly lowered all IgG subclasses and, similar to total IgG levels, IgG subclasses 1–4 
had a maximum change from baseline at visit 3, the final day of TPE (Figure 2). The mean 
maximum reduction of IgG subclasses was 65.1–74.8%. Amongst the four IgG subclasses 
return to baseline was fastest for IgG3 which recovered by 3 weeks. IgG 1, 2, and 4 did not 
recover to within 20% of the mean baseline value by visit 6.
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AChR autoantibodies
Titers of AChR autoantibodies demonstrated considerable variability at baseline (median 9.9 
nmol/L, range 0.4–42.2). A mean maximum 71.0% reduction in AChR autoantibody titers 
was observed at visit 3, the final day of TPE (Figure 3). Three weeks post-TPE, the mean 
titers remained 35.9% reduced from baseline. There was no difference in the mean AChR 
autoantibody to total immunoglobulin ratio from baseline through visit 6 (stable at 0.01).
Protective and vaccination antibodies
To determine the effect of TPE of titers on antibodies elicited by vaccination, we measured 
antibody levels for Varicella Zoster, Epstein Barr virus, Diptheria Toxin, and Tetanus Toxoid 
(Figure 4). The measured antibodies were detectable in all patients prior to TPE. Similar to 
the other measured Igs, protective antibody levels reached a nadir on the final day of TPE 
and most exhibited an equivalent return towards baseline. About half of the patients 
exhibited a transient drop of diphtheria antibodies below levels associated with increased 
risk of infection (<0.1 U/mL) and these levels were slower to recover. Tetanus toxoid 
antibodies remained detectable in nearly all patients throughout the study. Only one patient, 
who had low titers of nearly all measured protective antibodies prior to TPE, had tetanus 
toxoid antibodies levels that stayed consistently low post-TPE. One patient had low EBV 
antibody levels at baseline and these levels remained below the threshold associated with 
protection throughout the study. The other patients maintained levels above protective 
thresholds during and after completion of TPE.
DISCUSSION AND CONCLUSIONS
Most of the scientific literature describing the effects of TPE on immunological parameters 
dates from the 1980s and early 1990s. Those studies typically described total 
immunoglobulins in healthy subjects following a single TPE procedure or autoantibody 
levels in heterogeneous patient populations (6, 12). More comprehensive studies evaluating 
the effects of TPE on total Ig, Ig subclasses, and autoantibody kinetics simultaneously in a 
patient cohort are lacking. This study addresses this need, demonstrating that TPE reliably 
reduces all mean Ig levels by approximately 70% in MG patients receiving TPE for an 
exacerbation of their disease.
The medical literature has somewhat conflicting data on the recovery of Ig levels following 
TPE. Most studies have reported data in healthy volunteers after a single treatment or in 
patients using TPE regimens that are not as commonly used in current clinical practice for 
acute MG exacerbations (e.g., weekly or biweekly exchanges) (5, 6). Animal studies and 
studies in some patients have reported an increase in Ig above baseline levels, a so-called 
“overshoot” (13–15). The mechanism of the overshoot has been hypothesized to be 
attributed to an enhanced synthesis of autoantibodies. Some investigators have suggested 
that the potential for an overshoot makes TPE a suboptimal acute therapy in autoimmune 
diseases compared with IVIg due to the potential for worsening of disease related to the 
overshoot. Alternatively, the addition of an immunosuppressive drug has been suggested as a 
means to prevent the excessive production of autoantibodies and clinical worsening.
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Throughout our study, we did not observe a consistent overshoot phenomenon in pathogenic 
antibody levels and there was no clear evidence of enhanced autoantibody synthesis as 
suggested by a stable ratio of AChR autoantibodies to total IgG. Ig levels, including AChR 
autoantibodies, approached within 20% of baseline levels in most cases after 6 weeks post-
TPE without ever fully recovering to the baseline (data not shown). Of note, our patients 
were also on immunosuppressive medications which may have affected AChR 
autoantibodies recovery following TPE, though doses remained as stable as possible, 
particularly through the first 3 weeks. In this setting, there was no suggestion that adding or 
raising immunosuppressive therapy is needed to prevent overshoot. In current clinical 
practice, most patients are already on some form of immunosuppressive therapy at the time 
of an exacerbation or immunosuppressive therapy will be added soon after starting a course 
of TPE due to the chronic nature of the disease. Thus, the potential for observing a post-TPE 
“overshoot” in the clinical care of patients not on immunosuppressive therapy is exceedingly 
uncommon.
The major exception to the observed recovery post TPE is IgG3, which showed a mean 
reduction of 21% from baseline at 3 weeks and 10% 6 weeks post-TPE. Prior studies in 
healthy adults suggest that the kinetics of IgG3 are different than the other IgGs. In these 
past studies the measured half-life of IgG1, IgG2, and IgG3 are approximately 20 days, 
whereas IgG3 is approximately 7 days (16, 17). Our data in MG patients support these 
findings and suggests that the faster recovery of IgG3 is related to a shorter half-life and 
increased fractional turnover of IgG3 that has been described in healthy individuals (17).
The predominant IgG subclass in AChR MG is IgG1 and a smaller fraction of IgG3 (18). In 
this study AChR autoantibodies did indeed follow the recovery pattern of IgG1. Though not 
included in this study, patients with muscle specific kinase autoantibody MG (MuSK MG) 
would be expected to have a recovery of MuSK autoantibodies following TPE similar to 
AChR MG patients. MuSK autoantibodies are predominantly IgG4 which recovered similar 
to IgG1 in this study.
Since IgG levels, including AChR autoantibodies, approach baseline levels after 6 weeks 
post-TPE, excluding other factors, one might expect patient worsening around this time. In 
our prior personal experience, this often holds true. Also, in a randomized trial of patients 
with mild to moderate MG, the duration of benefit following TPE was at least four weeks 
(19). If a patient relapses following TPE it will often occur approximately 5–6 weeks or later 
after TPE (20). Following a single course of TPE there are patients that remain stable 
beyond this time. This suggests that factors other than circulating autoantibodies, such as the 
cause of the exacerbation (e.g., medication related versus idiopathic exacerbation), 
measurement of plasma versus tissue pathogenic autoantibodies, or other immunopathologic 
factors, influence clinical status following a disease flare treated with TPE.
One patient in the study with new onset disease was found to have a thymoma. In this case, 
the patient had the expected response to TPE in terms of the reduction in IgG, AChR 
autoantibody titers, and clinical response. However, the clinical response was more transient 
with worsening noted approximately 3 weeks after completing the first TPE course and prior 
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to thymectomy. Some prior studies have shown less favorable responses to treatment in 
patients with thymoma, including TPE, though usually in malignant cases (20).
A unique aspect of this study was the measurement of protective antibodies. Protective 
antibodies remained detectable throughout the study and returned towards their pre-TPE 
level similar to the other measured IgGs. Although titers correlated with protection to 
varicella have not been established, antibody levels for diphtheria, EBV, and tetanus 
remained above thresholds associated with protection for most patients (21). Given that TPE 
is usually administered in discrete courses and the resilience of these protective antibodies, 
TPE should be safe and not put patients at serious risk of infection. The effect of chronically 
administered TPE on the risk of these infections is uncertain. Finally, the kinetics of 
protective antibody recovery was similar to pathogenic AChR autoantibodies, supporting the 
concept that AChR autoantibodies are produced by long-lived plasma cells that also underlie 
long term protection from infections.
In this study of patients with AChR MG, we show that TPE rapidly lowers all Igs, including 
AChR-Ab and protective Abs. Following a course of 5–6 TPE treatments a return to baseline 
occurs beyond 3 weeks for all IgGs, except IgG3, which recovers faster. There is no apparent 
need to add immunosuppressive therapy to prevent an overshoot of autoantibodies in MG, 
but immunosuppressive therapy may be indicated for long term management of a patient’s 
disease. Longitudinal studies looking for predictors of relapse after 6 weeks post-TPE may 
be helpful to improve patient management.
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Figure 1. Effect of TPE on Mean IgA, IgM, and total IgG in MG patients
Raw data (A) and percent change from the Baseline (B) are shown by visit. The dotted 
horizontal line in B indicates return of Igs to within 20% of the pre-TPE level. Visits 
occurring before during, and after a course of TPE are indicated by background shading.
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Figure 2. Effect of TPE on IgG subclasses
Mean IgG subclasses (IgG1–IgG4) in MG patients are shown in terms of percent change 
from Baseline. The dotted horizontal line indicates return of IgG subclasses to within 20% 
of the pre-TPE level. Visits occurring before during, and after a course of TPE are indicated 
by background shading.
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Figure 3. Effect of TPE on AChR autoantibodies
Mean AChR antibody titers in MG patients are shown in terms of percent change from 
Baseline. The dotted horizontal line indicates return of AChR antibody levels to within 20% 
of the pre-TPE level. Visits occurring before during, and after a course of TPE are indicated 
by background shading.
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Figure 4. Effect of TPE on protective antibodies against diptheria, tetanus, Epstein-Barr virus, 
and Varicella in MG patients
Mean data are shown for anti-Epstein-Barr virus capsid antigen IgG, and anti-varicella IgG 
(A) and anti-diptheria and tetanus toxoid IgG (B) are shown by visit. Visits occurring before 
during, and after a course of TPE are indicated by background shading.
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Table 1
Baseline demographics of enrolled MG patients (N=10)
Median Age in years, (range) 72.9 (20 – 86)
Male, N (%) 6 (60%)
Caucasian, N (%) 9 (90%)
Median Weight (kg), (range) 85.6 (50.0 – 100.1)
Median BMI (kg/m2), (range) 28.4 (20.2 – 32.4)
MG medications
 Acetylcholinesterase inhibitor 80%
 Corticosteroids 60%
 Oral immunosuppressants 50%
Median duration of MG in years, (range) 0.8 (0–38)
Baseline MGFA Severity Class IIa = 20%
IIIa = 30%
IIIb = 40%
IVa = 10%
Median MG-ADL, (range) 9 (6 – 12)
Median MG-Composite, (range) 21 (12 – 27)
Median MG-MMT, (range) 23 (11 – 81)
Median MG-QOL15, (range) 25 (18 – 43)
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